[go: up one dir, main page]

CL2018002458A1 - Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer (divisional solicitud 201600227) - Google Patents

Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer (divisional solicitud 201600227)

Info

Publication number
CL2018002458A1
CL2018002458A1 CL2018002458A CL2018002458A CL2018002458A1 CL 2018002458 A1 CL2018002458 A1 CL 2018002458A1 CL 2018002458 A CL2018002458 A CL 2018002458A CL 2018002458 A CL2018002458 A CL 2018002458A CL 2018002458 A1 CL2018002458 A1 CL 2018002458A1
Authority
CL
Chile
Prior art keywords
peptides
cells
nucleic acids
expression vectors
divisional application
Prior art date
Application number
CL2018002458A
Other languages
English (en)
Inventor
Toni Weinschenk
Steffen Walter
Jens Fritsche
Colette Song
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1313987.8A external-priority patent/GB201313987D0/en
Priority claimed from GBGB1403297.3A external-priority patent/GB201403297D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CL2018002458A1 publication Critical patent/CL2018002458A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

LA INVENCIÓN SE REFIERE A PÉPTIDOS, ÁCIDOS NUCLEICOS Y CÉLULAS PARA LA UTILIZACIÓN EN MÉTODOS INMUNOTERAPÉUTICOS. EN CONCRETO, EL DOCUMENTO EN ESTUDIO SE REFIERE A PÉPTIDOS, ÁCIDOS NUCLEICOS, VECTORES DE EXPRESIÓN, CÉLULAS HOSPEDADORAS, CURRIPOSICIONES FARMACÉUTICAS, UN MÉTODO PURA PRODUCIR DICHOS PÉPTIDOS, UN MÉTODO PARA PRODUCIR LINFOCITOS ACTIVADOS, LINFOCITOS T ACTIVADOS, UN MÉTODO PARA PRODUCIR UN TCR O STCR, UN AGENTE DE UNIÓN AISLADO, UN RECEPTOR DE LINFOCITO T ACTIVADO, Y SUS USOS PARA EL TRATAMIENTO CONTRA EL CÁNCER.
CL2018002458A 2013-08-05 2018-08-28 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer (divisional solicitud 201600227) CL2018002458A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862213P 2013-08-05 2013-08-05
GBGB1313987.8A GB201313987D0 (en) 2013-08-05 2013-08-05 Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GBGB1403297.3A GB201403297D0 (en) 2014-02-25 2014-02-25 Novel immunotherapy against several tumors, such as lung cancer, including NSCLC

Publications (1)

Publication Number Publication Date
CL2018002458A1 true CL2018002458A1 (es) 2018-10-12

Family

ID=60955422

Family Applications (6)

Application Number Title Priority Date Filing Date
CL2018002279A CL2018002279A1 (es) 2013-08-05 2018-08-10 Péptidos, ácidos nucleicos y células para la utilización en inmunoterapia contra el cáncer (solicitud divisional 201600227)
CL2018002458A CL2018002458A1 (es) 2013-08-05 2018-08-28 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer (divisional solicitud 201600227)
CL2018002494A CL2018002494A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización de inmunoterapia contra el cáncer (divisional solicitud 201600227)
CL2018002495A CL2018002495A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
CL2018002493A CL2018002493A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
CL2021001794A CL2021001794A1 (es) 2013-08-05 2021-07-06 Péptido, ácido nucleico, célula, composición farmacéutica, linfocito t activado, agente de unión aislado, y tcr, para su uso en inmunoterapia contra el cáncer; y métodos para producirlos (divisional de la solicitud no. 201600227)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018002279A CL2018002279A1 (es) 2013-08-05 2018-08-10 Péptidos, ácidos nucleicos y células para la utilización en inmunoterapia contra el cáncer (solicitud divisional 201600227)

Family Applications After (4)

Application Number Title Priority Date Filing Date
CL2018002494A CL2018002494A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización de inmunoterapia contra el cáncer (divisional solicitud 201600227)
CL2018002495A CL2018002495A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
CL2018002493A CL2018002493A1 (es) 2013-08-05 2018-08-31 Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
CL2021001794A CL2021001794A1 (es) 2013-08-05 2021-07-06 Péptido, ácido nucleico, célula, composición farmacéutica, linfocito t activado, agente de unión aislado, y tcr, para su uso en inmunoterapia contra el cáncer; y métodos para producirlos (divisional de la solicitud no. 201600227)

Country Status (19)

Country Link
US (19) US20170320913A1 (es)
JP (5) JP6646017B2 (es)
KR (2) KR20220045085A (es)
CN (4) CN118221800A (es)
AU (1) AU2022201167A1 (es)
CL (6) CL2018002279A1 (es)
CY (2) CY1122453T1 (es)
ES (6) ES3008994T3 (es)
HR (2) HRP20211852T1 (es)
HU (1) HUE057334T2 (es)
IL (5) IL300761A (es)
LT (1) LT3456339T (es)
MX (3) MX2018010565A (es)
MY (1) MY191939A (es)
PH (3) PH12018501901A1 (es)
PL (1) PL3456339T3 (es)
PT (1) PT3456339T (es)
RS (1) RS62602B1 (es)
SI (1) SI3456339T1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
HUE057334T2 (hu) * 2013-08-05 2022-05-28 Immatics Biotechnologies Gmbh Új immunterápia többféle tumor, például tüdõrák ellen, az NSCLC-t is beleértve
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
WO2020032153A1 (ja) * 2018-08-09 2020-02-13 第一三共株式会社 Ｈｓｐａ８遺伝子のプロモーター
MX2021004355A (es) * 2018-10-19 2021-05-31 Eth Zuerich Moleculas quimericas.
CN116024176A (zh) * 2020-07-14 2023-04-28 广州泛恩生物科技有限公司 基于tnfrsf18阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
CN112521484A (zh) * 2020-12-03 2021-03-19 佛山市第一人民医院（中山大学附属佛山医院） 结肠癌肿瘤特异tcr序列及其应用
CN112691195B (zh) * 2021-02-02 2023-03-14 黑龙江省科学院高技术研究院 Prpf8表达抑制剂在制备治疗肺癌的药物中的应用
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
CA2316079A1 (en) 1997-12-31 1999-07-08 Incyte Pharmaceuticals, Inc. Human regulatory proteins
US7094890B1 (en) 2000-03-10 2006-08-22 Novartis Ag Arthritis-associated protein
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2003016471A2 (en) 2001-08-13 2003-02-27 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2004018633A2 (en) * 2002-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Abca13 nucleic acids and proteins, and uses thereof
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
ATE511550T1 (de) * 2003-07-17 2011-06-15 Pacific Edge Biotechnology Ltd Marker zum nachweis von magenkrebs
US7811828B2 (en) 2004-01-28 2010-10-12 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumuor-associated
US20060019284A1 (en) 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
PL1642905T3 (pl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
SI1806359T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II
AU2007218158A1 (en) 2006-02-22 2007-08-30 Philogen Spa Vascular tumor markers
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
PL3042914T3 (pl) 2007-07-27 2019-01-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
WO2009036246A2 (en) 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
US8134459B2 (en) 2007-10-19 2012-03-13 Smiths Medical Asd, Inc. Wireless telecommunications system adaptable for patient monitoring
EP3085707B1 (en) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr binding peptides and their uses
EP2250287B1 (en) * 2008-02-19 2013-09-18 MDxHealth SA Detection and prognosis of lung cancer
EP2262530A4 (en) 2008-03-03 2012-12-05 Dyax Corp Metalloproteinase-12 TIE PROTEINS
AU2009234444A1 (en) 2008-04-11 2009-10-15 China Synthetic Rubber Corporation Methods, agents and kits for the detection of cancer
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2010037124A1 (en) * 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
WO2010045388A2 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
US20110189694A1 (en) * 2008-10-22 2011-08-04 Biomarker Design Forschungs Gmbh Methods for detection and diagnosis of a bone or cartilage disorder
CA2743473C (en) 2008-11-17 2022-06-14 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
CN101824400B (zh) * 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
US20110033516A1 (en) 2009-08-06 2011-02-10 Medical University Of South Carolina Methods and compositions for bone healing by periostin
US8281222B2 (en) 2009-08-07 2012-10-02 Via Technologies, Inc. Detection and correction of fuse re-growth in a microprocessor
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9028810B2 (en) 2010-12-20 2015-05-12 Ajou University Industry—Academic Cooperations Foundatin Composition for inducing migration of neural stem cells containing periostin as effective ingredient
HUE057334T2 (hu) * 2013-08-05 2022-05-28 Immatics Biotechnologies Gmbh Új immunterápia többféle tumor, például tüdõrák ellen, az NSCLC-t is beleértve
TWI777198B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10202111399YA (en) * 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

Also Published As

Publication number Publication date
US10479818B2 (en) 2019-11-19
JP2018038388A (ja) 2018-03-15
IL262509B (en) 2022-02-01
JP6646017B2 (ja) 2020-02-14
US20200031867A1 (en) 2020-01-30
IL280565A (en) 2021-03-25
MY191939A (en) 2022-07-19
US20170320913A1 (en) 2017-11-09
IL262509A (en) 2018-12-31
CN110041402B (zh) 2024-04-16
CL2018002494A1 (es) 2018-10-26
CL2021001794A1 (es) 2022-02-25
US10316063B1 (en) 2019-06-11
US20220281917A1 (en) 2022-09-08
PH12018501901A1 (en) 2019-04-15
IL269753B (en) 2021-03-25
US11859017B2 (en) 2024-01-02
JP2025000999A (ja) 2025-01-07
KR102383710B1 (ko) 2022-04-08
US11161880B2 (en) 2021-11-02
US11161878B2 (en) 2021-11-02
HUE057334T2 (hu) 2022-05-28
KR20220045085A (ko) 2022-04-12
US11161877B2 (en) 2021-11-02
JP7094572B2 (ja) 2022-07-04
US20200031870A1 (en) 2020-01-30
KR20200037457A (ko) 2020-04-08
JP7039044B2 (ja) 2022-03-22
PH12021551208A1 (en) 2022-02-14
CN118221800A (zh) 2024-06-21
CN110041403A (zh) 2019-07-23
ES3008994T3 (en) 2025-03-25
CN110041403B (zh) 2023-03-10
IL269753A (en) 2019-11-28
US20250066422A1 (en) 2025-02-27
IL300761A (en) 2023-04-01
CL2018002493A1 (es) 2018-11-09
CN109748953A (zh) 2019-05-14
US20190177369A1 (en) 2019-06-13
US20200031868A1 (en) 2020-01-30
US11814446B2 (en) 2023-11-14
IL295031B1 (en) 2023-04-01
HRP20211852T1 (hr) 2022-03-18
CY1124950T1 (el) 2023-01-05
SI3456339T1 (sl) 2022-01-31
RS62602B1 (sr) 2021-12-31
US11939400B2 (en) 2024-03-26
US10316062B1 (en) 2019-06-11
US10793602B2 (en) 2020-10-06
CN110041402A (zh) 2019-07-23
US10487116B2 (en) 2019-11-26
ES3009756T3 (en) 2025-03-31
US20200017551A1 (en) 2020-01-16
US11939401B2 (en) 2024-03-26
ES3010561T3 (en) 2025-04-03
US20220194984A1 (en) 2022-06-23
US10323065B1 (en) 2019-06-18
MX2021001914A (es) 2021-04-28
PH12020500433A1 (en) 2021-01-11
CY1122453T1 (el) 2021-01-27
CN109748953B (zh) 2022-09-02
IL280565B (en) 2022-09-01
US20240182522A1 (en) 2024-06-06
US20210253640A1 (en) 2021-08-19
JP2020010686A (ja) 2020-01-23
US20190169233A1 (en) 2019-06-06
ES3005785T3 (en) 2025-03-17
US11161879B2 (en) 2021-11-02
JP2020072717A (ja) 2020-05-14
LT3456339T (lt) 2021-12-10
MX2018010565A (es) 2021-11-16
US10160786B1 (en) 2018-12-25
CL2018002279A1 (es) 2018-09-14
PT3456339T (pt) 2021-12-09
ES3009064T3 (en) 2025-03-25
JP7572400B2 (ja) 2024-10-23
HRP20192262T1 (hr) 2020-03-06
US11866517B2 (en) 2024-01-09
PL3456339T3 (pl) 2022-03-21
MX2019011621A (es) 2019-12-05
US20220298207A1 (en) 2022-09-22
US20190322703A1 (en) 2019-10-24
ES2900004T3 (es) 2022-03-15
IL295031A (en) 2022-09-01
US20190177368A1 (en) 2019-06-13
US20190218254A1 (en) 2019-07-18
AU2022201167A1 (en) 2022-03-17
JP2022130482A (ja) 2022-09-06
CL2018002495A1 (es) 2018-10-26
US20190002504A1 (en) 2019-01-03
US20200031869A1 (en) 2020-01-30
IL295031B2 (en) 2023-08-01
US20220064220A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
CL2018002458A1 (es) Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer (divisional solicitud 201600227)
CL2022003264A1 (es) Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MX2022015821A (es) Nuevos receptores de celulas t y usos de los mismos.
CR20170282A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CL2019002939A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer (divisional solicitud 201801531)
MX2019006724A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
MX2022004082A (es) Anticuerpos biespecificos contra cd3 y cd20.
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
CR20160531A (es) Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (lma)
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
PE20191248A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CL2019002947A1 (es) Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer. (divisional solicitud 201801533)
CL2020001675A1 (es) Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346)
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso